SGHT vs. TMCI, DCTH, CLPT, NPCE, NYXH, SMLR, ZIMV, NNOX, TCMD, and LUNG
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Treace Medical Concepts (TMCI), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), NeuroPace (NPCE), Nyxoah (NYXH), Semler Scientific (SMLR), ZimVie (ZIMV), Nano-X Imaging (NNOX), Tactile Systems Technology (TCMD), and Pulmonx (LUNG). These companies are all part of the "medical equipment" industry.
Sight Sciences vs.
Treace Medical Concepts (NASDAQ:TMCI) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
Treace Medical Concepts has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.
Treace Medical Concepts has higher revenue and earnings than Sight Sciences. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 24.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 28.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Treace Medical Concepts had 7 more articles in the media than Sight Sciences. MarketBeat recorded 8 mentions for Treace Medical Concepts and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.74 beat Treace Medical Concepts' score of 0.73 indicating that Sight Sciences is being referred to more favorably in the news media.
Treace Medical Concepts received 6 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 45.61% of users gave Treace Medical Concepts an outperform vote while only 30.30% of users gave Sight Sciences an outperform vote.
Treace Medical Concepts has a net margin of -30.33% compared to Sight Sciences' net margin of -63.30%. Sight Sciences' return on equity of -47.28% beat Treace Medical Concepts' return on equity.
Treace Medical Concepts currently has a consensus price target of $10.14, indicating a potential upside of 18.89%. Sight Sciences has a consensus price target of $3.83, indicating a potential upside of 37.64%. Given Sight Sciences' higher probable upside, analysts clearly believe Sight Sciences is more favorable than Treace Medical Concepts.
Summary
Treace Medical Concepts beats Sight Sciences on 10 of the 16 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy SGHT Stock Free SGHT Stock Alerts